Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Next Previous
Trial Profile

Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin; Vinorelbine
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms JIPANG; JIPANG-TR

    • Most Recent Events

    • 13 Sep 2022 Results of final analysis of OS in the JIPANG study is presented here presented at the 47th European Society for Medical Oncology Congress
    • 24 Jun 2020 Results of exploratory study assessing relationship between tumor mutation profiles, including TMB and clinical outcome, of pemetrexed/cisplatin versus vinorelbine /cisplatin for completely resected stage II-IIIA non-squamous non-small-cell lung cancer in JIPAN study, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
    • 14 May 2020 the primary end point was changed from overall survival to recurrence-free survival because, with developments in subsequent chemotherapy, death events were too few to evaluate survival at the completion of patient accrual
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top